Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6NUT2

UPID:
D19L2_HUMAN

ALTERNATIVE NAMES:
Dpy-19-like protein 2; Protein dpy-19 homolog 2

ALTERNATIVE UPACC:
Q6NUT2; A4FVC1; B4E191; Q3ZCX2; Q6UWG8; Q96LZ9

BACKGROUND:
DPY19L2, known for its probable C-mannosyltransferase activity, mediates the C-mannosylation of tryptophan residues in proteins, playing a vital role in human reproductive biology. It is indispensable for proper spermatogenesis, influencing sperm head elongation and acrosome formation, and is involved in acrosome attachment to the nuclear envelope. The enzyme's specific functions highlight its significance in the process of reproduction.

THERAPEUTIC SIGNIFICANCE:
The enzyme DPY19L2 is crucial for normal spermatogenesis and is implicated in Spermatogenic failure 9, an infertility disorder stemming from spermatogenesis defects. The exploration of DPY19L2's functions offers promising avenues for developing treatments for infertility disorders caused by defects in spermatogenesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.